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Homozygosity for a Missense Mutation in SERPINH1,
which Encodes the Collagen Chaperone Protein HSP47,
Results in Severe Recessive Osteogenesis Imperfecta
Helena E. Christiansen,1,7 Ulrike Schwarze,2,7 Shawna M. Pyott,2 Abdulrahman AlSwaid,3
Mohammed Al Balwi,4 Shatha Alrasheed,3 Melanie G. Pepin,2 Mary Ann Weis,5 David R. Eyre,5
and Peter H. Byers2,6,*
Osteogenesis imperfecta (OI) is characterized by bone fragility and fractures that may be accompanied by bone deformity, dentinogen-
esis imperfecta, short stature, and shortened life span. About 90% of individuals with OI have dominantmutations in the type I collagen
genes COL1A1 and COL1A2. Recessive forms of OI resulting from mutations in collagen-modifying enzymes and chaperones CRTAP,
LEPRE1, PPIB, and FKBP10 have recently been identiﬁed. We have identiﬁed an autosomal-recessive missense mutation (c.233T>C,
p.Leu78Pro) in SERPINH1, which encodes the collagen chaperone-like protein HSP47, that leads to a severe OI phenotype. Themutation
results in degradation of the endoplasmic reticulum resident HSP47 via the proteasome. Type I procollagen accumulates in the Golgi of
ﬁbroblasts from the affected individual and a population of the secreted type I procollagen is protease sensitive. These ﬁndings suggest
that HSP47 monitors the integrity of the triple helix of type I procollagen at the ER/cis-Golgi boundary and, when absent, the rate of
transit from the ER to the Golgi is increased and helical structure is compromised. The normal 3-hydroxylation of the prolyl residue
at position 986 of the triple helical domain of proa1(I) chains places the role of HSP47 downstream from the CRTAP/P3H1/CyPB
complex that is involved in prolyl 3-hydroxylation. Identiﬁcation of this mutation in SERPINH1 gives further insight into critical steps
of the collagen biosynthetic pathway and the molecular pathogenesis of OI.Introduction
Osteogenesis imperfecta (OI [MIM 166200, 166210,
259420, and 166220]) or ‘‘brittle bone disease’’ ranges in
severity from lethal in the newborn period to only mild
increase in fracture frequency.1,2 OI is most often the result
of dominantmutations in the type I collagengenesCOL1A1
(MIM 120150) and COL1A2 (MIM 120160). A wide array of
mutations that affect the type I collagen triple helix (most
of which result in substitutions of glycine residues in the
uninterrupted Gly-X-Y triplet repeat of the 1014 residue
triple helical domain) and globular carboxy-terminal region
(C-propeptide) have been identiﬁed, and attempts have
beenmade to draw correlation between the site ofmutation
and severity of the phenotype.3,4 In spite of the large collec-
tion of mutations, the only clear genotype-phenotype
relationship is that premature termination codons in the
COL1A1 gene result in mild OI type I whereas almost all
mutations that result in collagen structural abnormalities
produce more severe phenotypes. Although there is more
tobeunderstoodabout type I collagenand thepathogenesis
of OI, the link between mutation and phenotype may lie
not in the more prevalent dominant forms of OI but in
the recently recognized recessive mutations that target key
points in the downstream collagen biosynthesis pathway.
In a fraction of individuals, OI is inherited in an auto-
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The Ameriencode four endoplasmic reticulum (ER) proteins that
lead to OI were identiﬁed recently5–10 (U. Schwarze et al.,
2009, Am. Soc. Hum. Gen., abstract; Y. Alanay et al., 2009,
Am. Soc. Hum. Gen., abstract). The triple helical domain,
which is characterized by a repeating Gly-X-Y triplet, of
the constituent chains of type I procollagen undergoes
a series of posttranslational modiﬁcations in the ER. These
include hydroxylation of Y-position prolyl residues at the
4-position of the ring, hydroxylation of some Y-position
lysyl residues, and glycosylation of hydroxylated lysyl
residues. A prolyl residue at position 986 of the proa1(I)
triple helix is hydroxylated at the 3-position of the ring
by a complex comprising cartilage-associated protein
(CRTAP [MIM 605497]), prolyl 3-hydroxylase (P3H1
[MIM 610339]), and cyclophilin B (CyPB [MIM 123841]),
encoded by the CRTAP, LEPRE1, and PPIB genes, respec-
tively. Recessive mutations leading to OI have been identi-
ﬁed in all three members of this complex (U. Schwarze
et al., 2009, Am. Soc. Hum. Gen., abstract).5–9 Mutations in
COL1A1, COL1A2, CRTAP, LEPRE1, and PPIB usually result
in overmodiﬁcation (probably excess lysyl hydroxylation
and glycosylation) of proa chains in the ER, presumably
because of their delayed assembly into trimers.
There is a subset of individuals with OI whose cells do
not overmodify collagen chains. Recessive mutations in
FKBP10 (MIM 607063), which encodes the ER-resident
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several individuals whose cells did not overmodify colla-
gens (Y. Alanay et al., 2009, Am. Soc. Hum. Gen., abstract,
and unpublished results). We screened 30 individuals
with OI whose cells did not produce overmodiﬁed type I
collagen for mutations in FKBP10 and SERPINH1, because
the latter is a collagen-binding protein and functions as a
chaperone in the ER. In one individual, we identiﬁed an
autosomal-recessive mutation in SERPINH1 (MIM 600943),
the gene that encodes HSP47, a chaperone-like protein for
collagens, and in two others we identiﬁed mutations in
FKBP10 (unpublished). A recessive mutation in SERPINH1
leading to an OI phenotype in Dachshunds was recently
identiﬁed by homozygosity mapping, but its molecular
mechanism was not characterized.11 Here we describe the
human mutation in SERPINH1 and its effect on type I
procollagen production and structure.
Material and Methods
Cell Culture, Isolation of DNA and RNA,
and Collagenous Protein Analysis
Human dermal ﬁbroblasts were obtained with appropriate consent
and cultured as previously described.12 DNA and RNA were
isolated with QIAGEN QIAamp DNA Mini kit and RNeasy Mini
kit, respectively, per the manufacturer’s instructions (QIAGEN,
Valencia, CA). Complementary DNA was synthesized from RNA
with Superscript II reverse transcriptase (Invitrogen, Carlsbad,
CA). Radiolabeling and analysis of collagenous proteins was per-
formed as previously described.12
Pulse-Chase Studies
Fibroblasts from the affected individual and a control were plated
at conﬂuence (250,000 cells) in 35 mm tissue-culture dishes in
Dulbecco Modiﬁed Eagle Medium (DMEM) supplemented with
10% fetal calf serum, allowed to attach overnight, and then incu-
bated in the presence of 50 mg/ml of ascorbic acid for 18 hr prior to
labeling. Conﬂuent cells were starved of proline with serum-free
medium supplemented with 50 mg/ml ascorbic acid for 1 hr,
then labeled in serum-free medium with 100 mCi/ml [2,3,4,5-3H]
proline (American Radiolabeled Chemicals, Inc., St. Louis, MO).
After 60 min in label, cells were rinsed twice with serum-free
medium with 50 mg/ml ascorbic acid, and fresh chase medium
was added that contained 10 mM proline. At 0, 20, 40, 60, and
120 min, the medium was collected and the cell layer scraped
into a separate tube in PBS, protease inhibitors were added to
both, and the collagenous proteins were precipitated with 50%
v:v ethanol and carrier collagen in the presence of 15 mM
iodoacetamide added to prevent new disulﬁde bond formation.
Precipitated proteins were suspended in SDS-sample buffer and
separated on 5% SDS-PAGE under nonreducing condition. The
gels were ﬁxed, treated with Enhance (Perkin Elmer, Waltham,
MA), and dried. Radiolabeled bands were visualized by autoradiog-
raphy. Band density was quantitated with the ImageJ software.
Subject Selection
Because of its role as a collagen chaperone and collagen binding
protein,13 SERPINH1 was sequenced in DNA from 30 individuals
whose cells made only normal type I collagen molecules via stan-
dard analytic methods.12 Of these, 24 had a diagnosis of OI type II
or OI type III, of whom 8 derived from consanguineous matings.390 The American Journal of Human Genetics 86, 389–398, March 1Five had OI type III/IV based on clinical description and of these
three had related parents. In one instance there was insufﬁcient
clinical information to identify the type of OI. FKBP10 was also
sequenced in all, and two individuals with OI type III had muta-
tions identiﬁed (unpublished results).
PCR and Sequencing
SERPINH1 exons and ﬂanking splice sites and intronic sequences
were ampliﬁed fromgenomicDNAby PCR and sequenced (primers
and conditions are available upon request). Sequences were
analyzed via Mutation Surveyor V3.20 (Softgenetics).
Western Blot and Immunocytochemistry
Dermal ﬁbroblasts were treated with 50 mg/ml of ascorbic acid
overnight in DMEM with 10% fetal calf serum. For western blot,
proteins were extracted by ethanol precipitation, separated by
SDS-polyacrylamide gel electrophoresis on 5% or 10% gel, and
transferred to nitrocellulose membrane. Membranes were probed
with the following antibodies: anti-HSP47 monoclonal (SPA470,
StressGen Biotechnologies, Ann Arbor, MI) (1:500) and anti-
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) (1:50). Perox-
idase-conjugated secondary antibodies were used and detected
with ECL Plus Western Blotting Detection System (GE Healthcare,
Piscataway,NJ). Immunocytochemistrywasperformedasdescribed
(Abcam protocols) with the following antibodies: anti-Hsp47
(1:5000), anti-PDI (StressGen Biotechnologies, Ann Arbor, MI)
(1:400), anti-bovine proa1(I) amino-propeptide (LF-9, 1:800),14
anti-58K Golgi protein (Abcam, Cambridge, MA) (1:1000), and
anti-KDEL (Abcam) (1:400). The anti-Hsp47 antibody was titrated
with mouse SERPINH1/ cell line KO-13, generously provided by
Dr. Nagata, Kyoto University, Kyoto, Japan.15
Proteasome Degradation Assays
Dermal ﬁbroblasts were treated with 50 mg/ml of ascorbic over-
night and then treated with 50 mMMG-132 proteasome inhibitor
(Calbiochem, La Jolla, CA) in serum-free medium with 50 mg/ml
ascorbate for 0–16 hr. In additional studies, dermal ﬁbroblasts
were treated with proteasome inhibitor MG-132 for 16 hr and
then with 100 mg/ml cycloheximide (CHX) and MG-132 or CHX
alone for an additional 8 hr to prevent further protein synthesis.
Proteins were harvested by ethanol precipitation as previously
described.12
Prolyl 3-Hydroxylation
The extent of prolyl 3-hydroxylation in proa1(I) chains was
measured as described by Morello et al.5
Thermostability Assay
Thermostability was determined as described by Pace et al.16
Protease Digestion Assay
Dermal ﬁbroblasts were plated to conﬂuency in 35 mm dishes and
labeled with 100 mCi/ml [2,3,4,5-3H]proline in serum-free
medium with 50 mg/ml ascorbic acid overnight. The medium
was collected and maintained at 37C, and secreted proteins
were digested with 200 mg/ml trypsin and 500 mg/ml chymo-
trypsin as previously described.15
Cyanogen Bromide Mapping
Cleavage of collagens with cyanogen bromide and peptide
mapping were performed as previously described.122, 2010
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Figure 1. X-Rays
Radiographs of the skull at age 1 year (A)
demonstrate diminished calvarial mineral-
ization and enlargement of the calvarial
vault. At birth, the chest (B) was small,
the ribs were thin and some had healing
fractures, one clavicle was bent, both
humeral bones had fractures, platyspon-
dyly was present, and overall mineraliza-
tion appeared diminished. By 1 year of
age (C and D), the ribs had become broad,
platyspondyly was still apparent with
diminished central mineralization of the
vertebral bodies, and the humeral bones
had a tubular shape, thin cortices, and
diminished mineralization. The deformity
and decreased mineralization of the bones
in the arms are apparent at 1 year (E), and
the minimal effect of pamidronate can
be seen. At 1 month (F), 1 year (G), and
28 months (H), there is rhizomelic short-
ening and limited modeling of the long
bones with very thin cortices. The lines
of increased mineralization reﬂect the
successive pamidronate infusions.Results
Clinical Report
The index case was the ﬁrst child born to a clinically
normal consanguineous Saudi Arabian couple and was
the only affected member in the extended family (Figures
1 and 2A). At about 28 weeks gestation, fetal ultrasound,
performed because the previous scans at an outside
hospital were not available, identiﬁed short bowed femora.
A repeat scan at 36 weeks and 5 days again demonstrated
short femora, low echogenicity of the calvarium, and a rela-
tively small chest. No internal organ abnormalities were
noted. There were no maternal medications taken and no
intercurrent illnesses during pregnancy.
The boywas born by elective cesarean section at 38weeks
gestation because of breech presentation; the Apgar scores
were 7 and 9 at 1 and 5 min, respectively. Birth weight
was 2.43 kg (10th–25th centile) and head circumference
was 33.5 cm (25th centile). Birth length was not recorded.
At birth he was noted to have a triangular face, relative
macrocephaly, bitemporal narrowing, blue sclerae, micro-
gnathia, and relatively short limbs with bowing at the
thighs. Radiographs of the chest at birth showed thin
ribs with healing fractures, a fracture of the right humerus,
a healing fracture of the left humerus, and platyspondyly
(Figure 1B). His fractures were managed by splinting and
analgesia. He had respiratory distress that required ventila-
tion for 1 day followed by nasal continuous positive airway
pressure for 2 weeks. At 1 week of age, he was noticed to
have a few localized skin blisters and bullae. A skin biopsyThe Ameriwas done to rule out epidermolysis bullosa simplex (EB
simplex [MIM 131900]); the histopathology report was
not consistent with EB. The bullae resolved shortly after
birth, no new bullae formed, and no additional studies
were completed.
At 3 weeks of age, pyloric stenosis was corrected by pylo-
romyotomy and antigastroesophageal reﬂux medications
were begun; he also had a bilateral inguinal hernia repair.
A skeletal survey at the age of 1 month was consistent
with the diagnosis of osteogenesis imperfecta. There were
multiple bone deformities and fractures that involved the
upper and lower extremities (Figure 1F) and ribs and gener-
alized osteopenia. He was treated with pamidronate infu-
sion at the age of 1 month with the supplement of vitamin
D3 (800 units) and elemental calcium for a total of 2 weeks
postinfusion. The pamidronate was initially given by infu-
sion every 3 to 4 months because of shortage of hospital
beds; this was changed to every 2 months at the age of
2 years. He was followed with regular renal ultrasounds,
and at the age of 1 year bilateral renal stones were noticed
with left pelviureteric junction obstruction that ultimately
required left nephrectomy because of hydronephrosis and
loss of renal function. He developed bilateral subdural
hematomas secondary to trauma at 1 year of age that was
ultimately managed by bilateral shunt. He had chronic
lung disease of unclear etiology and was admitted to the
hospital several times with pulmonary infections and
wheezing; from the age of 1.5 years he required 0.5–1 L
of continuous oxygen by nasal cannula to maintain
adequate oxygenation.can Journal of Human Genetics 86, 389–398, March 12, 2010 391
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Figure 2. Identification of a Homozygous Mutation in SERPINH1
(A) Family pedigree with consanguineous heterozygous parents (III-2 and III-3) and affected proband (IV-1, black arrow). Asterisks indi-
cate individuals studied.
(B) Homozygous c.233T>C, p.Leu78Promutation in exon 1 of SERPINH1 in proband, IV-1 (red box). Parents (III-2 and III-3) were hetero-
zygous at this site.
(C) The completely conserved 16 amino acid sequence in HSP47 that contains the leucine-to-proline substitution.The skeletal survey at the age of 1 year showed decreased
bone density, a narrow chest, broad ribs, thoracic scoliosis,
platyspondyly, deformity of all bones of the arms, a fracture
in the proximal shaft of the left femur, bilateral bowing of
tibiae and ﬁbulae, and osteopenia (Figures 1A, 1C–1E, and
1G). In the last skeletal survey at the age of 2 years and
4 months, there was thoracic scoliosis convex to the left,
generalized osteopenia, multiple healed fractures on the
left ribs, a fracture in the proximal shaft of the left
humerus, right femoral fractures of various ages, and bilat-
eral bowing of the femora, tibiae, and ﬁbulae (Figure 1H).
Bone mineral density of the lumber spine (L2–L4) was
0.101 g/cm2, 0.246 gm/cm2, and 0.210 g/cm2 at the ages
of 4 months, 1 year, and 2 years, respectively.
At the last examination at age 3 years and 5 months, he
weighed 7.81 kg (<5th centile), was 60 cm (<5th centile) in
length, and his head circumference was 49 cm (25th cen-
tile). He had relative macrocephaly, an open anterior
fontanel, high and prominent forehead, midface hypo-392 The American Journal of Human Genetics 86, 389–398, March 1plasia with shallow orbits, and blue sclerae. He had small
opalescent teeth consistent with dentinogenesis imper-
fecta. His chest was asymmetrical with bulging on the
left side and thoracic scoliosis convex to the left. He
had short upper and lower limbs, bowed thighs, and
valgus angulation at the knee with generalized joint laxity.
Neurologically he was alert, smiling, and cognitively intact
according to his mother. He rolled over with difﬁculty
and was unable to sit because of head lag and generalized
hypotonia. He was able to lift his legs to his head level
when lying on his back, and could hold, transfer, and
give objects. He had a high pitched voice, communicated
with single words, and had a vocabulary of around 30
words. His abdomen, cardiovascular system, and skin
were unremarkable.
At age 3 years and 6 months he had sudden unexplained
respiratory distress at home. Upon arrival to the hospital,
he was cyanosed and needed resuscitation and intubation
but died soon afterwards. No autopsy was performed.2, 2010
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Figure 3. Mutation of SERPINH1 Gener-
ates an Unstable Protein
(A) PCR ampliﬁcation of cDNA (35 cycles
for each) from control (C) and from
patient (IV-1) showed that the mRNA for
SERPINH1 was stable.
(B) Western blot analysis indicated that
HSP47 was signiﬁcantly decreased in
patient cells (IV-1).
(C) Immunocytochemistry with anti-
bodies to HSP47 and the ERmarker protein
disulﬁde isomerase (PDI) showed a normal
ER distribution of HSP47 in control cells
and a severe reduction in HSP47 in patient
cells (IV-1). The merged image (right
column) conﬁrms the absence of staining
for HSP47.
(D) Western blot showed partial rescue of
HSP47 beginning at ~8 hr of treatment
with proteasome inhibitor MG-132.
(E) HSP47 was stabilized after treatment
of cells with cycloheximide (CHX) and
MG-132 but in the absence of MG-132,
even with continuous presence of CHX,
previously stabilized HSP47 was destroyed.Mutation of SERPINH1 Results in Severe
Deforming OI
When analyses of the COL1A1, COL1A2, CRTAP, and
LEPRE1 genes were normal and collagens synthesized
by cultured ﬁbroblasts had normal modiﬁcation, we
sequenced FKBP10 and SERPINH1 and identiﬁed a homo-
zygous missense mutation in SERPINH1 (c.233T>C,
p.Leu78Pro) (Figures 2B and 2C). The phenotypically
normal parents of the proband were heterozygous for the
mutation (Figure 2B). The mutant SERPINH1 mRNA tran-
script was stable in dermal ﬁbroblasts (Figure 3A), but
western blot and immunocytochemical analysis showed
that the protein product HSP47 was signiﬁcantly decreased
in patient cells (Figures 3B and 3C). This was conﬁrmed
by western blot with a second antibody that recognized
an epitope near the carboxy-terminal end of HSP47 (data
not shown).
To determine the mechanism of protein degradation, we
treated ﬁbroblasts with proteasome inhibitor MG-132 for
0–16 hr and found that the mutant protein was partially
recovered beginning at 8 hr (Figure 3D). To conﬁrm that
mutant protein stabilization resulted from inhibition of
the proteasome and not abnormal gene activation, ﬁbro-
blasts were treated with MG-132 for 16 hr to allow mutantThe American Journal of Human Gprotein to accumulate and then with
MG-132 with cycloheximide (CHX)
or CHX alone to arrest translation
for an additional 2–8 hr. Cells treated
with both CHX and MG-132 main-
tained steady levels of HSP47. Cells
treated only with CHX showed reduc-
tion of HSP47 after 2–4 hr of CHX
treatment, indicating that reactiva-tion of the proteasome resulted in degradation of accumu-
lated mutant HSP47 (Figure 3E).
HSP47 Is Required for Normal Type I Procollagen
Localization but Not for Procollagen Chain
Modiﬁcation in the ER
HSP47 is known to interact with type I procollagen
although the nature of this interaction is still not com-
pletely understood.17 Mutations in other type I collagen
chaperones and modifying enzymes such as CRTAP,
LEPRE1, and PPIB usually lead to overmodiﬁcation of
collagen chains and decreased 3-hydroxylation of the
prolyl residue at position 986 of the triple helical domain
of proa1(I) chains.5–9 Analysis of collagen synthesis by
patient cells showed that the amount of type I procollagen
secreted and accumulated in the medium after a 16 hr
periodwas similar to that in controls. Therewas no increase
in intracellular storage, and posttranslational modiﬁcation
of type I procollagen chains was normal as evidenced by no
increase in band width of proa1(I) and proa2(I) chains
(Figure 4A). Although the amount of type I procollagen
secreted was similar to that in control cells (Figure 4A)
over a 16 hr period, the rate of secretion of type I procolla-
gen trimers into the mediummeasured during pulse-chaseenetics 86, 389–398, March 12, 2010 393
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Figure 4. Type I Procollagen Synthesis
and Secretion
(A) Labeling of cells with [3H]-proline
for 16 hr showed normal synthesis and
secretion of type I procollagen into the
culture medium and normal electropho-
retic mobilities of the constituent chains.
The chains of the procollagens were
separated under reducing conditions. The
collagens represent the procollagens after
digestion with pepsin and electrophoresis
under nonreducing conditions.
(B) Cells were labeled for 1 hr with [3H]-
proline then chased for up to 2 hr with
unlabeled proline. The secretion of the
trimers of type I procollagen showed a
delay in the rate of secretion in the patient
cells, quantitated in the graph to the right.studies over a 2 hr period was delayed by a short time when
compared to control (Figure 4B).
Tandemmass spectrometry analysis of secreted procolla-
gens showed that 3-hydroxylation of the prolyl residue
at position 986 of the proa1(I) triple helical domain was
similar in samples from patient and control cells (Figure S1
available online), suggesting that HSP47 function is inde-
pendent of the CRTAP/P3H1/CyPB complex responsible
for 3-hydroxylation.
The chains of type I procollagen are synthesized, hy-
droxylated, gycoslated, assembled, and folded into triple
helices in the ER. Trimeric type I procollagen molecules
are then transported into the Golgi where oligosaccharide
modiﬁcations occur. In control cells, type I procollagen
was detected in both ER and Golgi (Figure 5) by immuno-
ﬂuorescence. In patient cells, type I procollagen was less
abundant in the ER and accumulated in the Golgi
(Figure 5).
HSP47 Is Important for Proper Collagen Triple
Helix Stability
Posttranslational modiﬁcation of the triple helix was not
affected in patient cells. To determine whether loss of
HSP47 changed the conformation of the type I procollagen
triple helix, we examined the protease sensitivity of
secreted procollagen. The triple helical domain of type I
procollagen secreted by control cells is protease resistant
at 37C but the chains are degraded very rapidly when
denatured at 50C prior to protease treatment (Figure 6A).
In contrast, type I procollagen secreted from patient cells
was cleaved asymmetrically within the triple helical394 The American Journal of Human Genetics 86, 389–398, March 12, 2010domain when digested for 1 min at
37C with a combination of trypsin
and chymotrypsin (Figure 6A). These
fragments were completely lost after
5 min. These ﬁndings indicate that
HSP47 is a critical monitor of the ﬁnal
integrity of the triple helix. Analysis of
the type I collagen cleavage productsby cyanogen bromide peptide mapping indicated that the
major fragments seen were the products of cleavage near
the collagenase site (residues 775–776 in the triple helical
domains of each chain) (Figure 6B). Type III collagen
secreted frompatient cells was alsomore protease sensitive,
consistentwith a role for HSP47 inmonitoring helix forma-
tion of multiple collagen types.
When secreted procollagen molecules were harvested
by precipitation at 4C to promote stabilization of the
triple helix, the thermostability was increased by 0.5C
(Figure 6C) in cells from the patient. This suggests that at
37C, some type I procollagen molecules produced by
the HSP47-defective cells were abnormally folded and
accessible to proteases, but that if the procollagen trimers
were cooled prior to thermal denaturation, they formed a
stable arrangement that required a slightly higher temper-
ature to denature than molecules from control cells.Discussion
We identiﬁed a homozygous missense mutation in
SERPINH1 (c.233T>C, p.Leu78Pro), the gene that encodes
HSP47, in an individual with a severe deforming form
of OI that clinically ﬁts into the OI type III classiﬁcation.
The mutation resulted in degradation of virtually all
the abnormal HSP47 via the proteasome. Mutation of
SERPINH1 did not affect posttranslational modiﬁcation of
type I procollagen. It appeared to accelerate transit of type
I procollagen from the ER to the Golgi but slightly slowed
the overall transit time from inside the cell to the
Figure 5. Type I Collagen Accumulates
in the Golgi of HSP47 Mutant Cells
Immunocytochemistry with antibodies
against the N-propeptide of proa1(I), Golgi
marker 58K Golgi protein, and ER marker
KDEL showed localization of type I procol-
lagen to both Golgi and ER in control cells.
In patient cells (IV-1 rows), type I procolla-
gen was diminished in the ER and accentu-
ated in the Golgi.extracellular environment. The overall rate of type I procol-
lagen production was, nonetheless, effectively normal, but
the triple helical conformation of secreted type I collagen
was altered so that secreted type I collagen was protease
sensitive at one or more speciﬁc sites.
SERPINH1, a member of the serine proteinase inhibitor
gene family, encodes HSP47, which was initially identiﬁed
as a gelatin binding protein,18 named coligin. It is an
ER-resident protein and has an RDEL carboxy-terminal
sequence that provides the ER anchor. A mouse knockout
of SERPINH1 resulted in embryonic lethality and had
pleiotropic effects on collagen-containing tissues.15 The
mature processed form of type I procollagen was severely
reduced in whole tissue, and type I procollagen secreted
by a Serpinh1/ mouse ﬁbroblast cell line was protease
sensitive at 37C. In their studies, type I procollagen
accumulated as aggregates in the ER and secretion was
delayed.19 Cleavage of the proa1(I) N-propeptide was also
deﬁcient in Serpinh1/ ﬁbroblasts, consistent with local-
ized structural alterations of the substrate procollagen
sequences. Although HSP47 was severely reduced with
the human missense mutation Leu78Pro, a small amount
of protein could still be detected upon longer exposure of
western blot (data not shown). If the remaining protein
is functional, this may account for the less severe pheno-
type and differences in effects, such as type I procollagen
localization, in this individual. A mutation in Dachshunds
that also converted a leucine residue to a proline residue
(Leu326Pro), but near the carboxy-terminal end of HSP47,
resulted in a viable yet severe OI phenotype.11The American Journal of Human GIndividual proa chains are translo-
cated into the rough ER where
they undergo cotranslational modiﬁ-
cation (prolyl and lysyl hydroxyl-
ation, hydroxylysyl glycosylation,
and addition of oligosaccharides).
Sequences in the carboxy-terminal
propeptides guide type-speciﬁc associ-
ation of individual proa chains and
initiate propagation of the triple
helix. Trimers are trafﬁcked to the
Golgi where the glycosylated sites in
the carboxy-terminal propeptide are
further processed, and the trimers
are packaged for secretion. Mutations
in COL1A1 and COL1A2 that alter theprotein sequence, and those in CRTAP, LEPRE1, and PPIB,
each usually result in overmodiﬁcation of proa chains of
type I procollagen and retention of the trimeric molecules
in the ER, suggesting that mutations in these genes affect
early stages of the collagen biosynthesis, assembly, and
transport pathway. Mutation of SERPINH1 and FKBP10
(unpublished results) do not result in overmodiﬁed
collagen chains, indicating that the products of these
genes probably interact with type I procollagen molecules
at later stages of biosynthesis.
Although HSP47 can interact with individual chains, it
appears that the preferred substrate is the triple helical
domain of intact procollagen trimers.20,21 The missense
mutation we identiﬁed in SERPINH1 appears to have
several effects on type I procollagen production that we
could measure: rapid exit of type I procollagen trimers
from the ER to the Golgi, slightly delayed overall transit
time from the ER to the extracellular space, and failure to
mature all type I procollagen trimers so that they have
increased protease sensitivity. These ﬁndings suggest that
HSP47 may monitor the ﬁdelity of triple helical structure
at the ER/cis-Golgi boundary. How these changes result
in OI remains unclear, but changes in triple helical struc-
ture could affect ﬁbril assembly in the extracellular matrix
and lead to irregular mineralization and an OI phenotype.
It has become clear that OI phenotypes can result from
mutations in type I collagen genes and in genes that
encode proteins that modify the nascent chains, monitor
the secretory pathway, and assess triple helix formation
of type I procollagen. With the exception of the broadenetics 86, 389–398, March 12, 2010 395
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Figure 6. Mutation of HSP47 Affects
Protease Sensitivity and Thermostability
of the Type I Collagen Triple Helix
(A) Proteins in medium from cultured
dermal ﬁbroblasts labeled overnight with
[3H]-proline were digested for 1 or 5 min
with a combination of trypsin and chymo-
trypsin at 37C without prior cooling of
the sample. Pepsin-treated samples were
ethanol precipitated at 4C and then
digested for 2 hr at 16C. Procollagens
secreted into the culture medium by
control cells and then pretreated at 50C
for 15 min showed complete degradation
after treatment with trypsin/chymotrypsin
while procollagens from medium left at
37C had protease-resistant triple helical
domains. A subset of type I procollagen
molecules secreted from patient cells were
cleaved asymmetrically at 37C (the black
arrows indicate fragments seen in affected
cells and either not seen or in low abun-
dance in the control cells).
(B) Characterization by cyanogen bromide
peptide mapping of the cleavage products
of type I procollagen after trypsin/chymo-
trypsin treatment. The gel lanes from runs
equivalent to those in (A) were excised
and the bands cleaved with cyanogen
bromide. The larger of the new bands,
which migrated just below a2(I), was
derived from a1(I). The CB7 fragment is
missing and replaced by fragment A. The
size of the fragment indicates that the
parent peptide had been cleaved in CB7
near the mammalian collagenase cleavage
site (775–776 in the triple helical domain).
The smaller fragment in the parent gel was
derived from a2(I). The CB3-5 fragment
was shortened, fragment B, and the esti-
mated size indicated that it had been
cleaved in the region of the collagenase
cleavage site.
(C) Thermal stability of type I collagen
molecules. Cells were incubated overnight
with [3H]-proline in the presence of sodium
ascorbate (50 mg/ml). The secreted proteins
werecollectedbyprecipitationwithethanol
and then reheated to the temperatures
shown at which point they were treated
with trypsin/chymotrypsin for 2 min. The
thermostability of type I collagen was
increased in patient cells by about 0.5C (*).distinction between mutations that affect the amount of
type I procollagen produced (OI type I) and those that
result in production of abnormal molecules (other forms
of OI), the relationship between genotype and phenotype
has been difﬁcult to discern. Although ascertainment bias
cannot yet be excluded, it is striking that mutations in the
genes that encode modifying and monitoring proteins
cluster in the more severely affected individuals. The
substrate for all forms of OI appears to be type I collagen.
Mutations in the two genes that encode those proteins,
COL1A1 and COL1A2, suggest that monitoring triple helix
integrity is critical to the ‘‘prevention’’ of OI. Although
neither prolyl 4-hydroxylase nor peptidyl-disulﬁde isom-396 The American Journal of Human Genetics 86, 389–398, March 1erase (two components of the same protein) has yet been
implicated, they remain formal candidates for mutations
that result in OI because of their role in helix stabilization.
Mutations in the CRTAP, LEPRE1, and PPIB complex, like
mutations that alter the sequences of the triple helical
domain of the proa chains, usually result in overmodiﬁed
procollagens. The common mechanism to these is not yet
clear but may be the consequence of failure of the CyPB
protein, encoded by PPIB, to create the correct substrate
for the prolyl 4-hydroxylase. Because mutations in
SERPINH1 and FKBP10 do not result in overmodiﬁed
chains, they appear to act downstream from the former
mutations. Finally, the last of the known mutations that2, 2010
result in an OI phenotype occur in PLOD2 and result
in autosomal-recessive Bruck syndrome, which is charac-
terized by short stature, fractures, and contractures.22
Mutations in PLOD2 alter hydroxylation of lysyl residues
in the telopeptide domains of type I procollagen chains.
Although this is a modiﬁcation thought to occur on
chains prior to trimer assembly, its absence does not
interfere with helix formation and thus appears to act
further downstream, perhaps at the point of matrix miner-
alization.
Mutations at diverse sites along the type I collagen
triple helix are likely to interact differently with modify-
ing enzymes and chaperones to effect phenotypes. Even
closely spaced mutations within the triple helix could
interrupt binding to different chaperones or modifying
proteins. This might explain the sometimes marked varia-
tion in clinical outcome of these sequence alterations. We
noted that protease digestion of type I procollagen synthe-
sized by HSP47-deﬁcient cells generated a distinctive
ladder of cleavage products (Figure 6A), with a major early
cleavage near the collagenase cleavage site, which suggests
that HSP47 interacts with speciﬁc sites along the collagen
triple helix, consistent with the earlier identiﬁcation of
sites in the triple helical domain enriched in arginine as
candidate sites.21 Thus, mutations at HSP47 binding sites
in type I collagen could play an additive role and affect
clinical outcomemore thanmutations in nonbinding sites
and might help to explain the marked variation of pheno-
types along the chains that result from substitutions of
obligate glycines by small amino acids (serine, cysteine,
and alanine).3
Two ﬁnal points need to be stressed. First, even with the
identiﬁcation of genes in which mutations result in reces-
sive forms of OI, we and others have additional individuals
in which rigorous search for mutations in all known
causative genes has failed to identify the culprit. Thus,
more genes await characterization as harbors of causative
OI mutations and their identiﬁcation should help to better
understand the detailed molecular mechanisms of OI.
Second, these ﬁndings have implications for the strategies
by which individuals thought to have OI should be evalu-
ated at the molecular genetic level.Supplemental Data
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